Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Daniel Aaron Pollyea

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Pollyea, Daniel

One or more keywords matched the following items that are connected to Pollyea, Daniel

Item Type	Name
Academic Article	2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
Academic Article	Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.
Academic Article	Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience.
Concept	Remission Induction
Academic Article	Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Academic Article	Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.
Academic Article	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Academic Article	Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.
Academic Article	Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia.
Academic Article	Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Academic Article	Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Academic Article	Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
Academic Article	Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia.
Academic Article	Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy.
Academic Article	Complete, yet partial: the benefits of complete response with partial haematological recovery as an endpoint in acute myeloid leukaemia clinical trials.
Academic Article	The complete story of less than complete responses: The evolution and application of acute myeloid leukemia clinical responses.

Search Criteria

Remission Induction